These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27102230)

  • 1. DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype.
    Maurizi G; Mattiucci D; Mariani M; Ciarlantini M; Traini S; Mancini S; Olivieri A; Leoni P; Poloni A
    Br J Haematol; 2017 Jun; 177(5):818-822. PubMed ID: 27102230
    [No Abstract]   [Full Text] [Related]  

  • 2. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
    Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
    Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
    [No Abstract]   [Full Text] [Related]  

  • 3. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
    Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
    Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutics for myelodysplastic syndromes.
    List AF
    Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
    Boasman K; Simmonds MJ; Graham C; Saunthararajah Y; Rinaldi CR
    Ann Hematol; 2019 Jun; 98(6):1529-1531. PubMed ID: 30721335
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
    Pinto A; Zagonel V; Attadia V; Bullian PL; Gattei V; Carbone A; Monfardini S; Colombatti A
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():28-32. PubMed ID: 2483349
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
    Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
    Oncotarget; 2017 Apr; 8(17):28812-28825. PubMed ID: 28427179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in
    Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
    Leuk Lymphoma; 2019 Dec; 60(13):3316-3319. PubMed ID: 31204875
    [No Abstract]   [Full Text] [Related]  

  • 10. Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
    de Witte T
    Lancet Haematol; 2019 Apr; 6(4):e170-e171. PubMed ID: 30926075
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of action of demethylating and immune modulatory agents--discussion.
    Hofmann WK
    Cancer Treat Rev; 2011; 37 Suppl 1():S19-22. PubMed ID: 21621923
    [No Abstract]   [Full Text] [Related]  

  • 12. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.
    Yang Y; Li J; Geng Y; Liu L; Li D
    J Clin Lab Anal; 2021 Feb; 35(2):e23597. PubMed ID: 33080073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.
    Aanei CM; Catafal LC
    Cytometry A; 2018 Jul; 93(9):916-928. PubMed ID: 30211968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.
    Cheng JX; Chen L; Li Y; Cloe A; Yue M; Wei J; Watanabe KA; Shammo JM; Anastasi J; Shen QJ; Larson RA; He C; Le Beau MM; Vardiman JW
    Nat Commun; 2018 Mar; 9(1):1163. PubMed ID: 29563491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of demethylating and immune modulatory agents--conclusion.
    Müller-Tidow C; Hofmann WK
    Cancer Treat Rev; 2011; 37 Suppl 1():S23-4. PubMed ID: 21612872
    [No Abstract]   [Full Text] [Related]  

  • 17. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 18. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 19. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.